Nano Targeting and Therapy (NTT) Biopharma Inc. is a cutting-edge biotechnology company pioneering the use of mesoporous silica nanoparticles (MSNs) for the precise and efficient delivery of therapeutic molecules. The company’s innovative nanoparticle platform is designed to overcome biological barriers, enhancing the effectiveness of small molecules, peptides, nucleic acids, including antisense oligonucleotides and plasmids for transient gene therapy and other therapeutic approaches.
We develop our own new drugs and provide services to external companies including novel chemical entities and approved drugs through the 505B2 pathway. We welcomes strategic and business partners for the co-development of technologies and nano-pharmaceutical products.
Our vision is to tackle critical challenges and deliver improved solutions in drug delivery to address unmet medical needs. By combining innovative platform nanotechnology with bioactive ingredients, we are committed to create a new generation of effective nanomedicines that optimize therapies across a broad range of diseases.
NTT’s proprietary MSN technologies provide a versatile and biocompatible delivery platform designed to overcome major biological barriers and limitations of conventional methods for delivering small molecules, peptides, and nucleic acids, particularly in the fields of brain diseases, ocular and retinal diseases, oncology, and gene therapy.
Transient gene therapy for ocular genetic diseases via eye drops.
NTT is engaged in cooperation with multiple domestic and international companies for the co-development of technologies and products
Chairman & Co-Founder
Hardy Chan, PhD
Dr. Chan is a serial entrepreneur in the biotechnology industry and an accomplished scientist. He has close to 40 years of experience in the biotechnology industry, both in the US and Taiwan. He co-founded ScinoPharm and served as the CSO. Dr. Chan was the former CEO of Tanvex Biologics and co-founders of Allianz Bioscience, Helios Bioelectronics and NTT Biopharma. Before coming to Taiwan, Dr. Chan was the Vice President of Research and Director of Biotechnology at Syntex, an US company that was acquired by Roche. Dr. Chan has over 60 scientific publications in peer-reviewed journals and several granted patents.
Co-founder & MSN Pioneer
Chung-Yuan Mou, PhD
Prof. Mou is an Academician of Academia Sinica and Professor Emeritus at National Taiwan University. He is a pioneer in the field of mesoporous silica nanoparticles (MSNs) and their biomedical applications. Prof. Mou has published over 400 scientific articles and has received numerous honors and awards, including the TWAS Chemistry Award, the Cozzarelli Prize from the U.S. National Academy of Sciences, the Chemistry Medal from the Chinese Chemical Society (Taipei), and appointments as University Chair Professor and National Chair Professor at NTU.
Co-founder & Medical Advisor
Yun Yen, MD, PhD
Dr. Yun Yen is a renowned oncologist and former President of Taipei Medical University. He has extensive experience in cancer research and translational nanomedicine. Dr. Yen previously served as the Allen and Lee Chao Endowed Chair in Developmental Cancer Therapeutics at the City of Hope Comprehensive Cancer Center. He was also Chairman and CEO of Tanvex Biopharma and OBI Pharma, and Head of New Drug Development at the City of Hope Cancer Center. Dr. Yen holds memberships in numerous professional organizations and has published more than 140 abstracts and peer-reviewed journal articles.